Compare Ginkgo Bioworks Holdings Inc (DNA) vs Estee Lauder Companies Inc (EL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Estee Lauder Companies Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M), while Estee Lauder Companies Inc trades at $81.04 (market cap $29.25B). The key difference: Estee Lauder Companies Inc is far larger — about 49.5× Ginkgo Bioworks Holdings Inc's market cap, and Estee Lauder Companies Inc pays a 1.73% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | EL | |
|---|---|---|
Market Cap | $590.53M | $29.25B |
Sector | Health | Consumer Staples |
52-Week High | $16.14 | $119.61 |
52-Week Low | $5.48 | $67.23 |
Enterprise Value | $627.78M | $35.43B |
Dividend Yield | — | 1.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Estée Lauder (EL) trades at $81.15, down 1.83% on the day, with a bearish technical outlook and mixed fundamentals. The stock shows negative net income and declining revenue trends, though recent quarters have beaten EPS estimates. Analyst consensus is divided with a $90.60 price target, while technical indicators point to support near $80.
Outlook remains cautious due to profitability challenges and competitive pressures, but potential upside exists if cost controls and innovation drive margin recovery. Key risks include sustained earnings pressure and macroeconomic sensitivity in the beauty sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →
